Metastatic castration-resistant prostate cancer develops when prostate tumors continue to grow and spread despite therapies that suppress male hormones, which normally fuel prostate cancer progression. Although newer hormonal medicines, chemotherapy drugs and radiopharmaceuticals have improved care, the disease remains incurable once it reaches this stage. Antibody-drug conjugates, or ADCs, have revolutionized treatment for some breast, bladder and blood cancers, yet their effects in advanced prostate cancer have generally been modest and short-lived. UCLA scientists set out to determine whether existing ADC strategies could be made more effective without having to create an entirely new class of therapy.

An ADC is a molecular delivery system that links three components: an antibody, a chemical linker and a highly potent drug payload. The antibody recognizes a protein displayed on the surface of cancer cells, allowing the conjugate to bind to the tumor. After the cancer cell internalizes the ADC, the linker is broken down or chemically cleaved, releasing the payload inside the cell. This design concentrates a powerful cytotoxic drug where it is needed while potentially reducing exposure to healthy tissues. However, the approach can fail when tumors do not express enough of the target, rapidly repair the damage caused by the payload or activate survival mechanisms that prevent cell death.

The UCLA-led team first examined tumor samples from patients with advanced prostate cancer to understand whether multiple targets could be exploited at the same time. Their analysis showed that B7-H3, PSMA and STEAP1—three proteins already being investigated as targets for ADCs—were frequently present on the same cancer cells. This pattern is important because it suggests that different ADCs might be used in combination, or engineered to recognize multiple tumor-associated proteins, increasing the likelihood that cancer cells will be reached. At the same time, targeting proteins that are more abundant on tumor cells than on normal tissue could help maintain the precision that makes ADCs attractive.

The researchers then tested dozens of combinations involving payloads commonly used in ADC development. They were looking for drug pairs that produced synergy, meaning the combined effect was greater than would be expected from simply adding the activity of each drug individually. One combination consistently stood out: a DNA-damaging payload paired with a compound that inhibits BCL-XL. DNA-damaging agents can create breaks or lesions in the genetic material of cancer cells, but those cells may survive by activating molecular repair and stress-response pathways. BCL-XL acts as one of the proteins that helps prevent programmed cell death, or apoptosis, allowing damaged cells to remain alive.

Blocking BCL-XL appears to remove an important escape route. When prostate cancer cells were exposed to DNA damage while this survival protein was inhibited, they were less able to withstand the treatment and more likely to undergo apoptosis. In cell cultures, the combination caused significantly greater cancer cell death than either the DNA-damaging drug or the BCL-XL inhibitor alone. The same pattern emerged in mice implanted with advanced prostate tumors: combination treatment reduced tumor growth more strongly than single-agent therapy, supporting the idea that the two mechanisms reinforce one another inside the cancer cell.

The study also identified a possible genetic clue that could help determine which patients might benefit most. Tumors retaining an intact TP53 tumor suppressor gene responded particularly well to the treatment strategy. TP53 encodes the p53 protein, a central regulator of cellular stress responses that can halt cell division or promote apoptosis when DNA becomes severely damaged. Many cancers disable this protective system through TP53 mutations, potentially changing how they respond to DNA-damaging therapies. The researchers’ findings suggest that TP53 status may eventually become part of a biomarker strategy for selecting patients for ADC combinations, although this possibility must be tested prospectively in clinical trials.

The results also point to a broader principle in ADC design: the payload may be just as important as the target. Rather than treating an ADC as a fixed package consisting of one antibody and one chemotherapy drug, researchers can potentially match different payloads to the vulnerabilities of particular tumor types. In prostate cancer, pairing a DNA-damaging agent with a BCL-XL inhibitor may be especially effective because it attacks both the tumor’s genetic material and its ability to survive the resulting stress. Combining ADCs that recognize B7-H3, PSMA or STEAP1 could add another layer of pressure by increasing tumor-cell coverage.

The findings remain preclinical, and the treatment has not yet been shown to benefit patients. BCL-XL is also involved in the survival of some normal cells, meaning that safety, dosing and the management of possible side effects will be critical as the strategy moves toward human testing. The UCLA team is now engineering next-generation ADCs that incorporate the most promising payload combinations and evaluating additional ways to target prostate cancer cells. If these experiments are validated in clinical studies, the approach could transform ADCs from short-lived treatments into more durable, biologically tailored therapies for men with metastatic castration-resistant prostate cancer.

Subject of Research: Antibody-drug conjugate combinations targeting metastatic castration-resistant prostate cancer.

Web References: Journal of Clinical Investigation study; DOI link; UCLA Health Jonsson Comprehensive Cancer Center.

References: Semenova G. et al., Journal of Clinical Investigation, DOI: 10.1172/JCI200438.

Keywords: prostate cancer, metastatic castration-resistant prostate cancer, antibody-drug conjugates, ADCs, BCL-XL, PSMA, B7-H3, STEAP1, TP53, targeted cancer therapy, combination therapy, precision oncology.

Castration-resistant prostate cancer represents a stage of the disease where tumors continue to progress despite androgen deprivation therapy, which is the standard initial treatment modality. Taxanes, a class of chemotherapeutic agents including drugs like docetaxel and cabazitaxel, have been critical in extending survival for patients with CRPC. However, resistance to these agents often develops, leading to relapse and poor clinical outcomes. Understanding the molecular underpinnings that drive this resistance is therefore vital in developing new therapeutic strategies.

NNMT, an enzyme long studied for its role in cellular metabolism, particularly in methylation processes involving nicotinamide, has recently attracted attention in oncology due to its overexpression in various cancers. This study rigorously investigates how NNMT plays a critical role in modulating metabolic pathways that contribute to the development of taxane resistance in CRPC cells. By elucidating these mechanisms, the researchers offer a novel angle to target drug-resistant prostate tumors.

Using advanced biochemical assays and in vitro models, the research team demonstrated that NNMT levels were significantly elevated in taxane-resistant CRPC cell lines compared to their sensitive counterparts. This upregulation of NNMT was shown to reprogram cellular metabolism, leading to enhanced survival pathways and reduced apoptotic responses, which collectively underpin the cells’ ability to evade taxane-induced cytotoxicity.

Further molecular analyses revealed that NNMT activity leads to a shift in the balance of NAD+ metabolism. Since NAD+ functions as a critical coenzyme in cellular redox reactions and DNA repair, its altered homeostasis through NNMT-mediated methylation reactions profoundly impacts the cancer cells’ ability to counteract chemotherapy-induced stress. This metabolic remodeling facilitates a more robust defense mechanism, enabling tumor cells to survive and proliferate despite drug exposure.

Crucially, the study employed gene silencing techniques to knock down NNMT expression in resistant CRPC model systems. The results were striking: suppression of NNMT restored sensitivity to taxane chemotherapy, resulting in a marked increase in apoptosis and inhibition of tumor cell proliferation. This finding not only validates NNMT as a driver of resistance but also underscores its potential as a therapeutic target.

Importantly, the research team pursued in vivo studies using xenograft mouse models implanted with taxane-resistant prostate cancer tissues. Treatment regimens incorporating NNMT inhibitors alongside standard taxane chemotherapy yielded significant tumor regression compared to chemotherapy alone. This synergy points to a promising therapeutic avenue that could translate into improved clinical outcomes for patients with resistant disease.

The authors of the study also delved into the potential molecular partners interacting with NNMT, discovering complex networks involving key oncogenic signaling pathways, including PI3K/Akt and MAPK cascades. These pathways are well-recognized for their role in cancer survival and drug resistance, suggesting that NNMT may exert its pro-survival effects via modulation of these crucial intracellular circuits.

One compelling aspect of this research lies in the translational potential of NNMT inhibitors. The development of small molecule inhibitors targeting NNMT has been relatively unexplored until now, but the identification of NNMT as a pivotal player in taxane resistance could catalyze new drug discovery efforts. Such targeted therapies may complement existing treatment protocols, offering hope for patients who have exhausted conventional options.

The study also poses profound implications for diagnostic approaches. Elevated NNMT expression or activity could serve as a biomarker for anticipating taxane resistance, allowing oncologists to tailor therapeutic strategies more effectively and avoid futile chemotherapy cycles. The possibility of integrating NNMT monitoring in clinical practice adds a new dimension to personalized medicine in prostate cancer care.

Furthermore, this research highlights the intricate relationship between cancer metabolism and epigenetic regulation. NNMT’s enzymatic action influences methylation patterns across various molecules, hinting at widespread effects that might impact gene expression profiles linked to resistance phenotypes. Unraveling this epigenetic crosstalk could unveil additional therapeutic targets and enhance our understanding of cancer biology.

While these findings pave the way for innovative interventions, the authors caution that further studies are needed to delineate NNMT’s complex role in cancer metabolism and to develop clinically viable inhibitors. The challenges ahead include optimizing drug specificity, minimizing off-target effects, and conducting rigorous clinical trials to assess safety and efficacy in human subjects.

Concluding with a broader perspective, this work encapsulates the power of metabolic research in addressing drug resistance, a hurdle that continues to hinder the success of cancer therapies globally. By shining a spotlight on NNMT, Cevatemre and colleagues not only contribute to the scientific community’s understanding of CRPC pathophysiology but also offer a beacon of hope to patients confronting resistant forms of this formidable disease.

As the oncology field enthusiastically awaits subsequent developments inspired by this research, the identification of NNMT as a therapeutic target holds promise to redefine treatment paradigms for taxane-resistant castration-resistant prostate cancer, potentially ushering in a new era of precision medicine and improved survival outcomes.

Subject of Research: Nicotinamide N-methyltransferase as a therapeutic target in overcoming taxane resistance in castration-resistant prostate cancer.

Article Title: Nicotinamide N-methyltransferase as a therapeutic target in taxane-resistant castration-resistant prostate cancer.

Article References:
Cevatemre, B., Karyemez, E., Bulut, I. et al. Nicotinamide N-methyltransferase as a therapeutic target in taxane-resistant castration-resistant prostate cancer. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03110-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03110-1